Quick answer: latest quarter results, by ticker or company name

Home / CYBN / Company Profile

Cybin Inc

CYBN | Healthcare | AMEX
🌐 Website 📊 Reports 📈 Financials
$8.28
+0.10 (+1.22%)

Key Metrics

Market Cap
$413.02M
P/E Ratio
-2.20
EPS
$-3.77
Beta
N/A
Dividend Yield
N/A
ROE
-51.79%
Current Ratio
8.58

Company Information

Industry
Biotechnology

About Cybin Inc

Cybin Inc a biopharmaceutical company focuses on developing psychedelicbased therapeutics The companys development pipeline includes CYB003 a deuterated psilocybin analog to treat major depressive and alcohol use disorders CYB004 a deuterated dimethyltryptamine for treating anxiety disorders and CYB005 a phenethylamine derivative to treat neuroinflammation It has also developed EMBARK a psychedelicassisted psychotherapy The company is headquartered in Toronto Canada

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-11-13 $-1.39 $-0.74 87.8%
2025-08-13 $-1.10 $-0.51 115.7%
2025-06-30 $-1.02 $-0.51 100.0%
2025-02-10 $-0.38 $-0.51 +-25.5%

Financial Ratios (TTM)

Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
0.00%
ROA
-54.87%
Price to Book
1.95
Price to Sales
0.00